Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 15;211(10):1529-40.
doi: 10.1093/infdis/jiu647. Epub 2014 Nov 18.

Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type

Huong Q McLean  1 , Mark G Thompson  2 , Maria E Sundaram  1 , Burney A Kieke  1 , Manjusha Gaglani  3 , Kempapura Murthy  3 , Pedro A Piedra  4 , Richard K Zimmerman  5 , Mary Patricia Nowalk  5 , Jonathan M Raviotta  5 , Michael L Jackson  6 , Lisa Jackson  6 , Suzanne E Ohmit  7 , Joshua G Petrie  7 , Arnold S Monto  7 , Jennifer K Meece  1 , Swathi N Thaker  2 , Jessie R Clippard  2 , Sarah M Spencer  2 , Alicia M Fry  2 , Edward A Belongia  1
Affiliations

Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type

Huong Q McLean et al. J Infect Dis. .

Abstract

Background: During the 2012-2013 influenza season, there was cocirculation of influenza A(H3N2) and 2 influenza B lineage viruses in the United States.

Methods: Patients with acute cough illness for ≤7 days were prospectively enrolled and had swab samples obtained at outpatient clinics in 5 states. Influenza vaccination dates were confirmed by medical records. The vaccine effectiveness (VE) was estimated as [100% × (1 - adjusted odds ratio)] for vaccination in cases versus test-negative controls.

Results: Influenza was detected in 2307 of 6452 patients (36%); 1292 (56%) had influenza A(H3N2), 582 (25%) had influenza B/Yamagata, and 303 (13%) had influenza B/Victoria. VE was 49% (95% confidence interval [CI], 43%-55%) overall, 39% (95% CI, 29%-47%) against influenza A(H3N2), 66% (95% CI, 58%-73%) against influenza B/Yamagata (vaccine lineage), and 51% (95% CI, 36%-63%) against influenza B/Victoria. VE against influenza A(H3N2) was highest among persons aged 50-64 years (52%; 95% CI, 33%-65%) and persons aged 6 months-8 years (51%; 95% CI, 32%-64%) and lowest among persons aged ≥65 years (11%; 95% CI, -41% to 43%). In younger age groups, there was evidence of residual protection from receipt of the 2011-2012 vaccine 1 year earlier.

Conclusions: The 2012-2013 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation.

Keywords: influenza; medically attended influenza; vaccine effectiveness.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trivalent inactivated influenza vaccine effectiveness (VE) against influenza A(H3N2) (A) and influenza B/Yamagata (B), by year of age among persons aged 1–75 years. VE estimates were derived by including an interaction term between age and current-season vaccination status in the logistic model, in which age was represented as a restricted cubic spline function with 5 knots based on percentiles. The confidence intervals represent the uncertainty around the point estimate at each age. VE data are adjusted for network site, subject age, presence of high-risk health conditions, and calendar time (2-week intervals).
Figure 2.
Figure 2.
Age-specific trivalent inactivated influenza vaccine effectiveness (VE) of current and prior vaccination against influenza A(H3N2) among persons age ≥9 years, in which persons not vaccinated in either the current or prior season served as the reference group. VE data are adjusted for network site, subject age, presence of high-risk health conditions, and calendar time (2-week intervals). *P = .01 for comparison between the 2 vaccine groups. Abbreviation: CI, confidence interval.
Figure 3.
Figure 3.
Age-specific trivalent inactivated influenza vaccine effectiveness (VE) of current and prior vaccination against influenza B/Yamagata among persons age ≥9 years, in which persons not vaccinated in either the current or prior season served as the reference group. VE data are adjusted for network site, subject age, presence of high-risk health conditions, and calendar time (2-week intervals). Abbreviation: CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis 2009; 199:159–67. - PubMed
    1. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: comparison of interim and final results. Vaccine 2011; 29:6558–63. - PubMed
    1. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951–9. - PMC - PubMed
    1. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319–27. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2013. MMWR Morb Mortal Wkly Rep 2013; 62:32–5. - PMC - PubMed

Publication types

MeSH terms

Substances